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BACKGROUND: Stat3 is a member of the Janus-activated kinase/STAT signalling pathway. It normally resides in the cytoplasm and can be
activated through phosphorylation. Activated Stat3 (p-Stat3) translocates to the nucleus to activate the transcription of several
molecules involved in cell survival and proliferation. The constitutive activation of Stat3 has been shown in various types of
malignancies, and its expression has been reported to indicate a poor prognosis. However, the correlation between the constitutive
activation of Stat3 and the prognosis of cervical cancer patients has not been reported.
METHODS: The immunohistochemical analysis of p-Stat3 expression was performed on tissues from 125 cervical squamous-cell
carcinoma patients who underwent extended hysterectomy and pelvic lymphadenectomy, and the association of p-Stat3 expression
with several clinicopathological factors and survival was investigated.
RESULTS: Positive p-Stat3 expression was observed in 71 of 125 (56.8%) cases and was significantly correlated with lymph node
metastasis, lymph vascular space invasion, and large tumour diameter (44cm) by Fisher’s exact test. Kaplan–Meier survival analysis
showed that p-Stat3 expression was statistically indicative of a poor prognosis for overall survival (P¼0.006) and disease-free survival
(P¼0.010) by log-rank test.
CONCLUSION: These data showed that p-Stat3 expression in cervical cancer acts as a predictor of poor prognosis.
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Cervical cancer is the second most common malignant tumour
among women worldwide, with an estimated half million new cases
per year (Parkin et al, 2005). An aetiologic relationship between
high-risk human papillomavirus and cervical cancer has been firmly
established (zur Hausen, 2002), although the molecular mechanism
behind the progression or metastasis of this tumour remains
unclear. In recent years, major advances in understanding the
molecular basis of various types of cancer has helped bring about
the development of novel anticancer therapies. Consequently, much
interest has been focused on the signal transducer and activator of
transcription 3 (Stat3), a member of the Janus-activated kinase/
STAT signalling pathway (Levy and Darnell, 2002).
Signal transducer and activator of transcription 3 was first
identified as a DNA-binding factor that selectively binds to the
interleukin 6 (IL-6)-responsive element in the promoter of acute
phase genes from IL-6-stimulated hepatocytes (Wegenka et al,
1993). The Stat3 normally resides in the cytoplasm and can be
activated through phosphorylation by cytokines, growth factors,
and oncogenic proteins, such as IL-6, epidermal growth factor,
Ras, and Src (Zhong et al, 1994; Yu et al, 1995; Levy and Darnell,
2002; Yu and Jove, 2004). Activated Stat3 (p-Stat3) dimerises
and translocates to the nucleus, where its occupation of specific
DNA-binding sites results in the increased transcription of
several molecules that are involved directly in cell survival and
proliferation (Huang, 2007).
Constitutive activation of Stat3 has been shown in various types
of malignancies (Watson and Miller, 1995; Gouilleux-Gruart et al,
1996; Huang et al, 2000; Song and Grandis, 2000; Campbell et al,
2001; Scholz et al, 2003), and immunohistochemical expression
of p-Stat3 has been recognised as a predictor of poor survival.
In cervical cancer, however, little is known about the prognostic
relevance of p-Stat3, although Chen et al (2007) showed the
expression of p-Stat3 in an immunohistochemical study. There-
fore, the aim of this study was to investigate whether the
immunohistochemical expression of p-Stat3 can predict a poor
prognosis in patients with cervical squamous-cell carcinoma.
MATERIALS AND METHODS
Human tissue specimens and patient information
Tumour tissue was collected from 125 cervical cancer patients with
invasive squamous-cell carcinoma who had undergone extended
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shysterectomy with pelvic lymphadectomy at Kurume University
Hospital between 1996 and 2005. Normal cervical tissue was also
collected from five removed uteri without malignancy, which
served as a control. We studied the follow-up information through
May 2007 from patient medical records, with a median follow-up
period of 50 months. Histopathological diagnosis was based on
World Health Organization classifications, and clinical staging was
made according to the International Federation of Gynecology and
Obstetrics system. Postoperatively, adjuvant treatment was given
in the case of lymph node metastasis, lymph vascular space
invasion (LVSI), large tumour diameter (44cm), deep stromal
invasion (44/5), invasion into the parametrium, and positive
status for surgical margin. The use of tissue blocks and chart
review was approved by the Institutional Review Board of Kurume
University Hospital.
Immunohistochemical analysis
Sections (3mm thick) of formalin-fixed, paraffin-embedded
tumour specimens were deparaffinised in xylene and rehydrated
in graded alcohol. Antigen retrieval was carried out in Tris/EDTA
buffer (Dako Target Retrieval Solution, pH 9.0, DAKO, Kyoto,
Japan) by heating in a microwave oven for 30min at 991C. The
specimens were incubated at 41C overnight in a 1:25 dilution of
goat affinity-purified polyclonal antibody against p-Stat3 (Tyr-705,
sc-7993, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Slides
were washed three times in phosphate-buffer solution and further
incubated with a biotinylated secondary antibody for 30min at
room temperature. Next, the slides were rinsed with phosphate-
buffer solution and incubated for 5min with diaminobenzidine.
The sections were washed twice with distilled water, counter-
stained with haematoxylin for 1min, and washed once each with
distilled water and phosphate-buffer solution. Afterwards, the
slides were mounted and examined using a bright-field micro-
scope. Two investigators independently evaluated and interpreted
the results of immunostaining without knowledge of the clinical
data for each patient. In our condition, the positive rate of nuclear
staining was less than 10% in most cases and a significant
difference was not observed with regard to the intensity of
staining. Therefore, the existence of nuclear staining was
considered positive immunoexpression. We further categorised
the positive group into two subgroups for a detailed analysis of
lymph node metastatic patients. Local staining up to 5% of the
tumour area was defined as þ, and staining over 5% of the area
was defined as þþ, respectively.
Transfection of Stat3 small interfering RNA
Pre-designed siRNA (small interfering RNA) Reagent ON-TARGET
plus against STAT3 and siSTABLE Non-Targeting siRNA no. 1
were purchased from Dharmacon (Lafayette, CO, USA). Two sets
of siRNA were transfected into the cervical cancer cell line, SKG II
cells, with lipofectoAMINE 2000 (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s protocol. Cells were allowed to
proliferate in wells for 48h.
Western blotting
Cells were collected and lysed by LDS sample buffer (Invitrogen).
Protein concentrations were quantitated using the DC protein
assay kit (Bio-Rad, Hercules, CA, USA) according to the manu-
facturer’s protocol. Equal amounts of cellular proteins were
electrophoretically fractionated in 10% PAGE gels, transferred to
nitrocellulose membranes, and subjected to immunoblot analysis
with specific antibodies against p-Stat3 (Cell Signaling Technology,
Beverly, MA, USA) and Bcl-xL, vascular endothelial growth factor
(VEGF) (Santa Cruz Biotechnology), and b-actin (Sigma-Aldrich,
St Louis, MO, USA). Specific bands were visualised using the
chemiluminescence reagent kit (Amersham ECL and ECL advance
Western Blotting Analysis System; GE Healthcare, Chalfont
St Giles, UK). Specific bands were quantified by scanning
densitometry using the Image J1.34 software (NIH, Bethesda,
MD, USA) version 1.61. The expression status of each sample was
standardised by the expression status of b-actin.
Statistical analysis
Statistical analysis was performed using the SAS statistical package
version 9.1.3 (SAS Institute Inc., Cary, NC, USA). Survival curves
were generated using the Kaplan–Meier method, and comparisons
between survival curves were made using a log-rank test. Fisher’s
exact test was used to analyse discrete variables, and the
Jonckheere–Terpstra test was used to analyse the association
between the number of lymph nodes and the intensity of p-Stat3
immunoexpression. Multivariate survival analysis was conducted
using the Cox proportional hazard method. Only P-values less than
0.05 were considered statistically significant.
RESULTS
Patient characteristics
The 5-year overall and disease-free survival rates of all patients
were 86.1 and 83.1%, respectively. Patient characteristics were
presented in Table 1. Significantly low 5-year overall survival rates
were seen in patients with the factors of FIGO stage II, large
tumour diameter (44cm), deep stromal invasion (44/5), LVSI,
parametrial invasion, and lymph node metastasis (log-rank test,
data not shown). Significantly low rates of 5-year disease-free
survival were shown in patients with factors such as large tumour
diameter (44cm), deep stromal invasion (44/5), LVSI,
parametrial invasion, and lymph node metastasis (log-rank test,
data not shown).
Expression of p-Stat3 in cervical cancer tissue and normal
cervical tissue
Phosphorylated-Stat3 was expressed only in the nuclei of the
tumour cells (Figure 1A) and was not expressed in the nuclei
or cytoplasm of normal cells (Figure 1B). Nuclear staining of
p-Stat3 was observed in less than 10% of cells in most cases.
It was impossible to evaluate the intensity of p-Stat3 staining
because no significant difference of intensity status was observed.
Therefore, we defined all cases that show nuclear staining of
p-Stat3 as positive. No normal cervical tissues were stained with
p-Stat3.
Correlation between clinicopathologic factors and p-Stat3
expression
The correlation between clinicopathological features and positive
expression of p-Stat3 is summarised in Table 2. Positive expression
of p-Stat3 was significantly associated with large tumour diameter
(44cm), LVSI, and lymph node metastasis.
Correlation between lymph node metastases and p-Stat3
expression
Of the 32 patients with lymph node metastasis, 14 had one node,
7 had two nodes, and 11 had three or more nodes with metastasis.
The percentage of p-Stat3 expression status in each group is shown
in Figure 2. The relationship between p-Stat3 expression and these
three groups was significant, accounting for ordered categories on
both factors (P¼0.022; Jonckheere–Terpstra test).
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During the follow-up on 125 patients (with a median follow-up
of 50 months), 18 patients (14.4%) developed recurrence and
16 patients (12.8%) died of disease. Among the 125 tumours,
54 tumours (43.2%) were negative and 71 (56.8%) were positive for
p-Stat3 expression. The overall and disease-free survival rates were
determined using the Kaplan–Meier method. The 5-year overall
survival rate for patients with positive expression of p-Stat3 and
negative expression of p-Stat3 was 79.2 and 95.3%, respectively.
The overall survival rate was significantly higher in patients with
p-Stat3-negative tumours than in those with p-Stat3-positive
tumours (P¼0.006; log-rank test; Figure 3A). Similarly, the
5-year disease-free survival rate for patients with positive p-Stat3
expression and negative p-Stat3 expression was 76.8 and 92.3%,
respectively, and the disease-free survival rate in patients with
negative tumours was significantly higher than that in patients
with positive tumours (P¼0.010; log-rank test; Figure 3B).
However, positive p-Stat3 expression was not an independent
prognostic factor in multivariate analysis for overall and disease-
free survival (data not shown).
Eighteen of the 125 patients in our study developed recurrence
during the follow-up period. Of these, 12 had recurrence at a
distant site and 6 had local recurrence. Positive expression of
p-Stat3 was found in 10 (83.3%) tumours of distant recurrence and
5 (83.3%) tumours of local recurrence. There was no correlation
between p-Stat3 expression and the pattern of recurrence.
Figure 1 Immunoexpression of p-Stat3 in cervical cancer specimen (A), and normal cervical tissue (B). Only tumour cell nuclei were stained.
Table 2 Correlation between clinicopathologic variables and p-Stat3
expression using Fisher’s exact test
Variable n p-Stat3 positive (%) P-value
FIGO stage
I 101 53 (52.5) 0.006
II 24 18 (66.7)
Tumour size
p4cm 109 56 (51.4) 0.001
44cm 16 15 (93.8)
Stromal invasion
p4/5 86 45 (52.3) 0.173
44/5 39 26 (66.7)
LVSI
Absent 60 26 (43.3) 0.004
Present 65 45 (69.2)
Parametrium invasion
Absent 115 63 (54.8) 0.185
Present 10 8 (80.0)
LN metastasis
Absent 93 46 (49.5) 0.007
Present 32 25 (78.1)
LN¼lymph nodes; LVSI¼lymph vascular space invasion.
Table 1 Clinical and pathological characteristics
Characteristics Number (%)
Age, Median 47 (19–77)
o47 62 (49.6)
X47 63 (50.4)
FIGO stage
Ib1 90 (72.0)
Ib2 11 (8.8)
IIa 11 (8.8)
IIb 13 (10.4)
Tumour size
p4cm 109 (87.2)
44cm 16 (12.8)
Stromal invasion
p4/5 86 (68.8)
44/5 39 (31.2)
LVSI
Absent 60 (48.0)
Present 65 (52.0)
Parametrium invasion
Absent 115 (92.0)
Present 10 (8.0)
No. of metastatic LN
None 93 (74.4)
1 14 (11.2)
2 7 (5.6)
X3 11 (8.8)
Adjuvant therapy
None 62 (49.6)
RT 40 (32.0)
CCRT 9 (7.2)
CT 2 (1.6)
CT+RT 12 (9.6)
CCRT¼concurrent chemoradiation; CT¼chemotherapy; LN¼lymph nodes;
LVSI¼lymph vascular space invasion; RT¼radiotherapy.
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the expression of Stat3
Expression of p-Stat3 in all five cervical cancer cell lines was
confirmed by western blotting analysis (data not shown).
Transfection of siRNA against Stat3 into cervical cancer cell
line, SKG II, induced the inhibition of expression of pStat3.
Furthermore, the expression of Bcl-xL and VEGF, which are
reported to be downstream molecules of Stat3, was decreased
(Figure 4).
DISCUSSION
In this study, we found that Stat3 was activated in 56.8% of cervical
squamous-cell carcinomas in immunohistochemical analysis and
the expression of activated Stat3 (p-Stat3) significantly correlated
with a worse prognosis in patients with this disease by univariate
analysis. Immunoexpression of p-Stat3 has been recognised as a
predictor of poor survival in other malignancies (Horiguchi et al,
2002; Masuda et al, 2002; Rosen et al, 2006; Yang et al, 2007), but,
to our knowledge, the correlation between the p-Stat3 expression
and prognosis in patients with cervical cancer has not been
reported. It has been shown that p-Stat3 immunoexpression was
significantly associated with lymph node metastasis or tumour size
in other malignancies (Masuda et al, 2002; Kusaba et al, 2005;
Suiqing et al, 2005; Shah et al, 2006). Some clinicopathological
parameters such as FIGO stage, tumour size, deep stromal
invasion, LVSI, parametrium invasion, lymph node metastasis,
and the number of metastatic lymph nodes have been reported as
predictors of poor prognosis in cervical cancer (Sakuragi et al,
1999; Waggoner, 2003; Kim et al, 2005). Therefore, we examined
the possible correlation between such parameters and p-Stat3
expression in cervical cancer specimens, and found that p-Stat3
expression significantly correlated with lymph node metastasis,
LVSI, and large tumour size (44cm) in these patients. These
factors might contribute to a worse prognosis in patients with Stat3
activation. On the other hand, no independent prognostic factor
for overall survival was identified by multivariate analysis. Deep
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Figure 2 Correlation between the number of metastatic lymph nodes
and p-Stat3 expression. The percentages of ‘þþ,’ ‘þ,’ and negative
p-Stat3 expression in each group are plotted.
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factor for disease-free survival. Although p-Stat3 expression was
not an independent prognostic factor for either overall survival or
progression-free survival, probably because of the correlation with
other clinicopathological factors in our study, it was interesting to
observe that the hazard ratio was the highest in the significant
prognostic factor by univariate analysis (data not shown). This
result indicated that p-Stat3 expression can be an important factor
to predict prognosis.
Only one immunohistochemical study has been reported on
p-Stat3 expression in cervical cancer (Chen et al, 2007), in which
the researchers reported that 25 specimens (24.0%) showed
positive immunoexpression of p-Stat3 in 104 cervical cancer
specimens. This was a low occurrence rate compared with our
result. This difference might be attributed to the histologic subtype
or to the definition of positive expression; their data included
other histological subtypes such as adenocarcinoma and micro-
invasive carcinoma. They also defined weak-staining specimens as
having a negative expression. Their report showed that p-Stat3
expression did not significantly correlate with any clinico-
pathological factors such as patient’s age, tumour grade, disease
stage, lymph node metastasis, or histological type. However,
information on clinicopathological factors seemed insufficient to
draw any conclusions; approximately half the data on tumour
grade, disease stage, and lymph node metastasis were not
identified, and the researchers did not mention the prognosis of
patients with p-Stat3 immunoexpression.
Although our result indicated that the activation of Stat3
contributed to a poor prognosis, the mechanism of constitutive
activation of Stat3 has not been clarified well in cervical cancer. It
is reported that the autocrine and/or paracrine system by IL-6,
stimulation of EGF or Src (Zhong et al, 1994; Yu et al, 1995),
mutation or overexpression of Stat3 (Bromberg, 2002; Huang et al,
2005) results in constitutive activation of Stat3 in other
malignancies. Although a similar mechanism is considered in
cervical cancer, there is no report other than that of Wei et al
(2003) that revealed the activation of Stat3 mediated by IL-6.
Furthermore, Wei et al (2003) showed that the IL-6-mediated
VEGF expression had been suppressed by Stat3 inhibition with a
Stat3 dominant-negative mutant (DNStat3). In other malignancies,
it has been suggested that the Stat3 signalling pathway regulates
tumour progression by regulating downstream genes crucial to
angiogenesis, proliferation, invasion, and immune evasion (Huang,
2007). Chen et al (2007) showed that apoptosis had been induced
by the inhibition of Stat3 with DNStat3 or JSI-124, a small
molecular inhibitor of the Janus-activated kinase/STAT pathway in
cervical cancer. Furthermore, they showed a significant correlation
of expression between p-Stat3 and antiapoptotic molecules such as
BcL-xL, Mcl-1, and Survivin in immunohistochemical analysis. We
also showed that the inhibition of p-Stat3 expression resulted in a
downregulation of Bcl-xL and VEGF by western blotting analysis.
Recently, several inhibitors against Stat3 activation have been
established that showed the induction of apoptosis or cell-cycle
arrest in cancer cells, or decreased tumour volumes in vivo
(Turkson et al, 2005; Xi et al, 2005; Duan et al, 2006; Hussain et al,
2007). Stat3 targeted therapy seems to be a promising new strategy
for the treatment of cervical cancer.
In conclusion, p-Stat3 immunoexpression was found to be a
potent prognostic factor of cervical cancer. Stat3 might be a target
of molecular therapy in cervical cancer.
ACKNOWLEDGEMENTS
This work was supported in part by the Fukuoka Obstetrics and
Gynecology Researcher’s Charity Foundation Fund of Japan.
REFERENCES
Bromberg J (2002) Stat proteins and oncogenesis. J Clin Invest 109:
1139–1142
Campbell CL, Jiang Z, Savarese DM, Savarese TM (2001) Increased
expression of the interleukin-11 receptor and evidence of STAT3
activation in prostate carcinoma. Am J Pathol 158: 25–32
Chen CL, Hsieh FC, Lieblein JC, Brown J, Chan C, Wallace JA, Cheng G,
Hall BM, Lin J (2007) Stat3 activation in human endometrial and cervical
cancers. Br J Cancer 96: 591–599
Duan Z, Bradner JE, Greenberg E, Levine R, Foster R, Mahoney J,
Seiden MV (2006) SD-1029 inhibits signal transducer and activator of
transcription 3 nuclear translocation. Clin Cancer Res 12: 6844–6852
Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse JF, Capiod JC,
Delobel J, Weber-Nordt R, Dusanter-Fourt I, Dreyfus F, Groner B,
Prin L (1996) STAT-related transcription factors are constitutively
activated in peripheral blood cells from acute leukemia patients.
Blood 87: 1692–1697
Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M (2002)
Activation of signal transducer and activator of transcription 3 in renal
cell carcinoma: a study of incidence and its association with pathological
features and clinical outcome. J Urol 168: 762–765
Huang HF, Murphy TF, Shu P, Barton AB, Barton BE (2005) Stable expres-
sion of constitutively-activated STAT3 in benign prostatic epithelial cells
changes their phenotype to that resembling malignant cells. Mol Cancer
4: 2
Huang M, Page C, Reynolds RK, Lin J (2000) Constitutive activation of stat
3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol
79: 67–73
Huang S (2007) Regulation of metastases by signal transducer and activator
of transcription 3 signaling pathway: clinical implications. Clin Cancer
Res 13: 1362–1366
Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W,
Heimberger AB (2007) A novel small molecule inhibitor of signal
transducers and activators of transcription 3 reverses immune tolerance
in malignant glioma patients. Cancer Res 67: 9630–9636
Kim JH, Kim HJ, Hong S, Wu HG, Ha SW (2005) Post-hysterectomy radio-
therapy in FIGO stage IB-IIB uterine cervical carcinoma. Gynecol Oncol
96: 407–414
Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T,
Sekine I (2005) Expression of p-STAT3 in human colorectal adenocarci-
noma and adenoma; correlation with clinicopathological factors. J Clin
Pathol 58: 833–838
Levy DE, Darnell Jr JE (2002) Stats: transcriptional control and biological
impact. Nat Rev Mol Cell Biol 3: 651–662
Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K,
Tomita K, Komiyama S, Weinstein IB (2002) Constitutive activation of
signal transducers and activators of transcription 3 correlates with cyclin
D1 overexpression and may provide a novel prognostic marker in head
and neck squamous cell carcinoma. Cancer Res 62: 3351–3355
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002.
CA Cancer J Clin 55: 74–108
Rosen DG, Mercado-Uribe I, Yang G, Bast Jr RC, Amin HM, Lai R, Liu J (2006)
The role of constitutively active signal transducer and activator of trans-
cription 3 in ovarian tumorigenesis and prognosis. Cancer 107: 2730–2740
Sakuragi N, Satoh C, Takeda N, Hareyama H, Takeda M, Yamamoto R,
Fujimoto T, Oikawa M, Fujino T, Fujimoto S (1999) Incidence and
distribution pattern of pelvic and paraaortic lymph node metastasis in
patients with Stages IB, IIA, and IIB cervical carcinoma treated with
radical hysterectomy. Cancer 85: 1547–1554
Scholz A, Heinze S, Detjen KM, Peters M, Welzel M, Hauff P, Schirner M,
Wiedenmann B, Rosewicz S (2003) Activated signal transducer and
activator of transcription 3 (STAT3) supports the malignant phenotype
of human pancreatic cancer. Gastroenterology 125: 891–905
Shah NG, Trivedi TI, Tankshali RA, Goswami JA, Jetly DH, Kobawala TP,
Shukla SN, Shah PM, Verma RJ (2006) Stat3 expression in oral squamous
cell carcinoma: association with clinicopathological parameters and
survival. Int J Biol Markers 21: 175–183
Song JI, Grandis JR (2000) STAT signaling in head and neck cancer.
Oncogene 19: 2489–2495
Study of activated Stat3 in cervical cancer
S Takemoto et al
971
British Journal of Cancer (2009) 101(6), 967–972 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sSuiqing C, Min Z, Lirong C (2005) Overexpression of phosphorylated-
STAT3 correlated with the invasion and metastasis of cutaneous
squamous cell carcinoma. J Dermatol 32: 354–360
T u r k s o nJ ,Z h a n gS ,M o r aL B ,B u r n sA ,S e b t iS ,J o v eR( 2 0 0 5 )An o v e l
platinum compound inhibits constitutive Stat3 signaling and induces cell
cycle arrest and apoptosis of malignant cells. JB i o lC h e m280: 32979–32988
Waggoner SE (2003) Cervical cancer. Lancet 361: 2217–2225
Watson CJ, Miller WR (1995) Elevated levels of members of the STAT
family of transcription factors in breast carcinoma nuclear extracts.
Br J Cancer 71: 840–844
Wegenka UM, Buschmann J, Lutticken C, Heinrich PC, Horn F (1993)
Acute-phase response factor, a nuclear factor binding to acute-phase
response elements, is rapidly activated by interleukin-6 at the
posttranslational level. Mol Cell Biol 13: 276–288
Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY (2003)
Interleukin-6 promotes cervical tumor growth by VEGF-dependent
angiogenesis via a STAT3 pathway. Oncogene 22: 1517–1527
Xi S, Gooding WE, Grandis JR (2005) In vivo antitumor efficacy of STAT3
blockade using a transcription factor decoy approach: implications for
cancer therapy. Oncogene 24: 970–979
Yang SF, Wang SN, Wu CF, Yeh YT, Chai CY, Chunag SC, Sheen MC,
Lee KT (2007) Altered p-STAT3 (tyr705) expression is associated with
histological grading and intratumour microvessel density in hepato-
cellular carcinoma. J Clin Pathol 60: 642–648
Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, Jove R
(1995) Enhanced DNA-binding activity of a Stat3-related protein in cells
transformed by the Src oncoprotein. Science 269: 81–83
Yu H, Jove R (2004) The STATs of cancer – new molecular targets come of
age. Nat Rev Cancer 4: 97–105
Zhong Z, Wen Z, Darnell Jr JE (1994) Stat3: a STAT family member
activated by tyrosine phosphorylation in response to epidermal growth
factor and interleukin-6. Science 264: 95–98
zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to
clinical application. Nat Rev Cancer 2: 342–350
Study of activated Stat3 in cervical cancer
S Takemoto et al
972
British Journal of Cancer (2009) 101(6), 967–972 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s